title: [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
abstract: We prospectively evaluated the effectiveness of desensitization therapy for cases showing side-effects to antituberculous drugs (Isoniazid and Rifampicin) according to the guideline proposed by the Treatment Committee of the Japanese Society for Tuberculosis. Nineteen patients (23-88 years old, male 9, female 10) who had experienced adverse effects after receiving antituberculous drugs and underwent desensitization therapy between August 1998 and March 2000 were studied. Underlying diseases were 14 cases of pulmonary tuberculosis, 2 cases of cervical tuberculous lymphadenitis, 1 case of pulmonary atypical mycobacteriosis, 1 case of pulmonary tuberculosis and tuberculous pleuritis, 1 case of pulmonary tuberculosis and tuberculous lymphadenitis. The regimens of treatment for tuberculosis were INH + RFP + EB in 8 cases, INH + RFP + EB + PZA in 7 cases, INH + RFP + SM in 2 cases, INH + RFP + SM + PZA in 1 case, and INH + RFP in 1 case. Adverse reactions were 8 cases of eruption, 7 cases of drug fever, 3 cases of drug fever and eruption, and 1 case of drug fever and cervical lymphadenopathy. The causative drugs suggested from DLST or the clinical course were RFP in 17 cases and INH in 8 cases. The clinical effect of desensitization therapy for these antituberculous drugs was good in 14 out of the 17 cases (82%) for RFP, and in 6 out of 8 cases (75%) for INH. The effectiveness rate of the present desensitization therapy according to the guideline of the Japanese Society for Tuberculosis was almost equal to that of previous desensitization therapy, and the clinical results were almost same in present and previous studies despite the different methods of administration of the antituberculous drugs.
authors.affiliation: Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School Kawasaki Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kobashi
authors.forename: N
authors.initials: N
authors.lastname: Okimoto
authors.forename: T
authors.initials: T
authors.lastname: Matsushima
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Shishido
authors.forename: S
authors.initials: S
authors.lastname: Kawahara
authors.forename: E
authors.initials: E
authors.lastname: Shigeto
authors.forename: H
authors.initials: H
authors.lastname: Takeyama
authors.forename: T
authors.initials: T
authors.lastname: Kuraoka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects*; D007564:Japan; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D014376:Tuberculosis / Q000188:drug therapy; D014378:Tuberculosis Societies
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin